ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Afyren SAS (ALAFY.PA)
Afyren SAS stock price today, ATLAS forecast and fair value
Basic Materials · Specialty Chemicals · Euronext Paris · France
€2.24▲ +0.68%
Prices as of Oct 26, 2026 · EUR
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Afyren SAS in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Afyren SAS
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Afyren SAS a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between €2.02 and €2.44; in 9 out of 10, between €1.71 and €2.88. Estimated annual volatility is 50%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- €92.9M
- Market cap (USD)
- $104M
- 52-week high
- €3.24
- 52-week low
- €2.07
- Revenue (12 months)
- €2.5M
- Net margin
- -200.7%
- Beta
- 0.62
What this means
ATLAS does not publish a fair value for ALAFY.PA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ALAFY.PA has traded between €2.07 and €3.24. Today it is 30.9% below that high and 8% above its low.
Its beta is 0.62: it tends to move less than the market.
About the company
AFYREN SAS provides biobased products to replace petroleum-based molecules in France. It offers acetic, propionic, butyric and isobutyric, valeric and isovaleric, and caproic acids.
Want to see everything about Afyren SAS?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Afyren SAS do?
AFYREN SAS provides biobased products to replace petroleum-based molecules in France. It offers acetic, propionic, butyric and isobutyric, valeric and isovaleric, and caproic acids.
What is the chance ALAFY.PA goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, ALAFY.PA ends the month between €2.02 and €2.44.
How big is Afyren SAS and what is its P/E ratio?
Afyren SAS's market capitalization is €92.9M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is ALAFY.PA?
ATLAS estimates annual volatility at 50%. In a typical month, half of the outcomes end between €2.02 and €2.44.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer